Back to Search
Start Over
Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer.
- Source :
-
Expert opinion on investigational drugs [Expert Opin Investig Drugs] 2017 May; Vol. 26 (5), pp. 551-561. Date of Electronic Publication: 2017 Apr 13. - Publication Year :
- 2017
-
Abstract
- Introduction: Fibroblast growth factor receptor (FGFR) due to its central role in regulating cell survival, is a promising target for cancer therapeutics. Dysregulation of the FGFR pathway has been observed in several malignancies, including non-small cell lung cancer (NSCLC) particularly in patients with squamous histology. Areas covered: The aim of this article is to review the most relevant findings of clinical trials investigating drugs targeting FGFR pathway: such as FGFR tyrosine kinase inhibitors (TKIs), FGFR monoclonal antibodies and FGF ligand traps in NSCLC patients. Expert opinion: At present, clinical activity of drugs targeting FGFR in NSCLC is disappointing. Further studies are needed in order to better identify patients who might benefit from these drugs and to clarify the mechanisms of resistance to these compounds.
- Subjects :
- Animals
Carcinoma, Non-Small-Cell Lung pathology
Carcinoma, Squamous Cell drug therapy
Carcinoma, Squamous Cell pathology
Drug Design
Drug Resistance, Neoplasm
Drugs, Investigational pharmacology
Humans
Lung Neoplasms pathology
Molecular Targeted Therapy
Receptors, Fibroblast Growth Factor antagonists & inhibitors
Antineoplastic Agents pharmacology
Carcinoma, Non-Small-Cell Lung drug therapy
Lung Neoplasms drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1744-7658
- Volume :
- 26
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Expert opinion on investigational drugs
- Publication Type :
- Academic Journal
- Accession number :
- 28388262
- Full Text :
- https://doi.org/10.1080/13543784.2017.1316714